Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

PRO MEDICUS LIMITED Director's Dealing 2018

Mar 19, 2018

65579_rns_2018-03-19_89c404ad-c109-407e-a182-7744c3450417.pdf

Director's Dealing

Open in viewer

Opens in your device viewer

Appendix 3Y Change of Director’s Interest Notice

Listing Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

Name of entity Pro Medicus Limited ABN 25 006 194 752

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director Sam Aaron HUPERT
Date of last notice 08 May 2014

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest Direct
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest. Ordinary fully paid shares in Pro MedicusLimited held by Sam Aaron HUPERT
Date of change 14 March 201815 March 201816 March 201819March 2018
No. of securities held prior to change 30,107,660 ordinary shares consisting off:-30,072,660 ordinary shares heldunder Sam Aaron HUPERT35,000 ordinary shares held underAlltogether Superannuation Fund
Class Ordinary shares
Number acquired Nil
Number disposed 14 March 2018 – 31,500 ordinary shares15 March 2018 – 5,000 ordinary shares16 March 2018 – 13,500 ordinary shares19 March 2018–950,000 ordinary shares
  • See chapter 19 for defined terms.

Appendix 3Y Page 1

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Value/ConsiderationNote: If consideration is non-cash, provide details and estimated valuation 14 March 2018 – $8.5193 per share15 March 2018 – $8.4872 per share16 March 2018 – $8.4411 per share19 March 2018 – $8.00 per share
No. of securities held after change 29,107,660 ordinary shares consisting off:-29,072,660 ordinary shares heldunder Sam Aaron HUPERT35,000 ordinary shares held underAlltogether Superannuation Fund
Nature of changeExample: on-market trade, off-market trade, exercise of options, issue ofsecurities under dividend reinvestment plan, participation in buy-back On market trade – 14, 15 & 16 March 2018Off market trade – 19 March 2018

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract N/A
Nature of interest N/A
Name of registered holder(if issued securities) N/A
Date of change N/A
No. and class of securities to whichinterest related prior to changeNote: Details are only required for a contract in relationto which the interest has changed N/A
Interest acquired N/A
Interest disposed N/A
Value/ConsiderationNote: If consideration is non-cash, provide details and anestimated valuation N/A
Interest after change N/A
  • See chapter 19 for defined terms.

Appendix 3Y Page 2

11/3/2002

Appendix 3Y Change of Director’s Interest Notice

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailedabove traded during a+closed period where prior writtenclearance was required? No
If so, was prior written clearance provided to allow thetrade to proceed during this period? N/A
If prior written clearance was provided, on what date wasthis provided? N/A

For and on behalf of Pro Medicus Limited

==> picture [133 x 62] intentionally omitted <==

Clayton Hatch Company Secretary 20 March 2018

  • See chapter 19 for defined terms.

Appendix 3Y Page 3

11/3/2002